We recently demonstrated that as-needed use of acetaminophen (versus ibuprofen) was not associated with a higher incidence of asthma exacerbations or worse asthma control in young children with mild persistent asthma. 1 However, given prior epidemiological observations of more frequent acetaminophen use and greater asthma impairment in children, 2 it remains unclear whether there are subgroups of asthmatic children at increased risk for poorer outcomes with acetaminophen exposure. The purported mechanism linking asthma and acetaminophen is a reduction in the antioxidant, glutathione, which conjugates acetaminophen for excretion. While this process is crucial for detoxification, it also irreversibly consumes glutathione stores, resulting in increased and prolonged circulation of highly reactive intermediates (i.e., "oxidant stress").
To the Editor
We recently demonstrated that as-needed use of acetaminophen (versus ibuprofen) was not associated with a higher incidence of asthma exacerbations or worse asthma control in young children with mild persistent asthma. 1 However, given prior epidemiological observations of more frequent acetaminophen use and greater asthma impairment in children, 2 it remains unclear whether there are subgroups of asthmatic children at increased risk for poorer outcomes with acetaminophen exposure. The purported mechanism linking asthma and acetaminophen is a reduction in the antioxidant, glutathione, which conjugates acetaminophen for excretion. While this process is crucial for detoxification, it also irreversibly consumes glutathione stores, resulting in increased and prolonged circulation of highly reactive intermediates (i.e., "oxidant stress").
Abnormalities in glutathione and arginine metabolic pathways have been described in asthma, albeit in isolation, 3, 4 but each may potentially disrupt the balance of endogenous oxidation-reduction (redox) reactions and contribute to oxidant stress. Whereas glutathione is a tri-peptide thiol antioxidant, arginine is a conditionally essential amino acid that functions as the obligate substrate for nitric oxide production through the actions of the nitric oxide synthase (NOS) enzymes. The paradigm uniting these mechanisms involves Snitrosoglutathione, an endogenous airway smooth muscle relaxant that is decreased in the airways of patients with asthma. Low glutathione contributes to dysfunction of NOS enzymes, resulting in decreased coupling of nitric oxide to glutathione to form Snitrosoglutathione, with increased reactive nitrogen species formation. In addition, low arginine bioavailability results in decreased substrate availability for NOS isoforms, resulting in less S-nitrosothiol formation and increased bronchoconstriction. Inflammation simultaneously upregulates NOS and the arginine-consuming enzyme arginase, found to be elevated in children with asthma. 4 Arginase metabolizes arginine away from nitric oxide production towards ornithine and downstream by-products of proline and polyamines which can contribute to airway remodeling and smooth muscle proliferation. Arginine/Ornithine is a biomarker of arginase activity found to be a better reflection of arginine bioavailability than arginine alone. 5 We therefore questioned whether systemic glutathione, arginine and ornithine might be useful biomarkers for prediction of asthma exacerbation in children. We hypothesized that systemic glutathione levels would associate with measures of arginine bioavailability, and decreased glutathione and arginine availability would associate with more frequent asthma exacerbations in children treated with acetaminophen. We performed a secondary analysis of our aforementioned clinical trial in preschool children with mild persistent asthma (NCT01606319). 1, Details of that study are provided in the Online Repository. Blood samples were obtained at randomization after a 2-8 week run-in with inhaled fluticasone or placebo; parents were also discouraged from administering over-the counter acetaminophen or ibuprofen during the run-in period. Blood samples were analyzed for glutathione (reduced plus oxidized forms) and arginine and ornithine as previously described. 6 Plasma and erythrocyte samples were available from 261 of 300 children; features of these children and baseline glutathione, arginine and ornithine values are shown in Table E1 . Correlations between these values are shown in Figure E1 . Glutathione values were modestly positively correlated with ornithine in the plasma, while arginine and ornithine values were highly positively correlated in both the plasma and erythrocytes in raw analyses and after logarithmic transformation to account for outliers ( Figure E1 ). Baseline glutathione, arginine and ornithine values did not differ between children treated with fluticasone versus placebo during the run-in period ( Figure E2 ) and were also not associated with demographics such as age group or features of allergic sensitization or asthma impairment (Table 1 ). There were also no associations between baseline glutathione, arginine and ornithine values and asthma exacerbations over the 48-week treatment period in univariate analyses (Figure 1 ) or after adjustment for age group and acetaminophen versus ibuprofen treatment assignment (Table E2 ). Plasma and erythrocyte values, stratified by acetaminophen versus ibuprofen treatment assignment and the number of exacerbations, are provided in Tables E3 and E4 . Baseline levels of glutathione, arginine and ornithine also failed to predict the time to first exacerbation in univariate analyses or after adjustment for as-needed acetaminophen versus ibuprofen treatment and asthma controller medication receipt (i.e., daily inhaled fluticasone, as-needed inhaled fluticasone or montelukast) prior to the exacerbation onset ( Figure E3 ). Logarithmic transformation of the biomarkers did not yield different results in time to exacerbation analyses (data not shown).
In this secondary analysis, we failed to detect associations between baseline systemic measures of glutathione, arginine and ornithine and asthma exacerbations in young children with mild persistent asthma. A strength was the prospective assessment of exacerbations in the context of highly supervised asthma controller therapy, thus reducing the potential confounding effects of asthma medication adherence or other factors that might contribute to poor asthma control. To our knowledge, this is also the first study to characterize plasma and erythrocyte concentrations of glutathione, arginine and ornithine in young children with mild persistent asthma. Although variability in the concentrations was noted, the plasma levels are similar to those reported in children with asthma. 4, 7 Nonetheless, there are limitations, including the lack of a healthy control group and the cross-sectional nature of the sample collection. We are therefore unable to comment on the longitudinal stability of the measures during health or acute exacerbations. Our focus on systemic samples is also a limitation since airway and systemic redox pools are not necessarily in equilibrium, particularly in cases of milder asthma in which inflammation is likely localized to the airways. Because this study evaluated young children with mild persistent asthma only, associations in older children or in children with more severe asthma remain unknown. Indeed, other reports have noted decreased expression of acetaminophenmetabolizing enzymes and glutathione in severe asthmatic children after acetaminophen exposure. 8 These prior reports do provide mechanistic feasibility to reports of asthma-related complications associated with frequent acetaminophen use. Likewise, arginine bioavailability has also been associated with airflow abnormalities in severe asthma 9 and may play an important role during acute exacerbations. 4 Our findings are not definitive, but we have provided some novel insight regarding glutathione and arginine bioavailability in young children with mild asthma. Further studies are still needed in heterogeneous \populations to better understand temporal associations between these biomarkers, developmental maturation, and exacerbations of asthma in early childhood. Table 1 Plasma and erythrocyte glutathione, arginine and ornithine concentrations according to baseline features. Data represent the mean ± SD. Results are not statistically significant at p < 0.05. 
